FTH
Faeth Therapeutics, Inc.Company Information
- Company Name
- Faeth Therapeutics, Inc.
- CIK
- CIK0001829802
- Category
- <br>Emerging growth company
- Ticker: Exchange
- FTH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FTH
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-01
- Last sale
- 2026-06-01
- Shares purchased (TTM)
- 40,102
- Shares sold (TTM)
- 102,898
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,073,582
- Shares outstanding
- 5,643,222
- Ownership
- 249.39%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 32.71%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 27 | 152 | 9 | 11 | 13 | 10 | 10 | 19 | 12 | 11 | 13 | 11 | ||||||
| Available For Sale Securities Debt Securities Current | 160 | 50 | 13 | 14 | 16 | 24 | 31 | 28 | 40 | 47 | 53 | 61 | ||||||
| Prepaid Expense Current | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 1 | 2 | ||||||
| Other Assets Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 189 | 204 | 22 | 26 | 30 | 36 | 42 | 48 | 54 | 60 | 67 | 74 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | ||||||
| Finance Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 189 | 205 | 23 | 28 | 32 | 38 | 45 | 53 | 60 | 67 | 74 | 82 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 8 | 9 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | ||||||
| Employee Related Liabilities Current | 1 | 4 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 10 | 14 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | ||||||
| Finance Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 10 | 14 | 4 | 5 | 4 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | ||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | 7 | 328 | - | - | - | - | - | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 642 | 316 | 302 | 301 | 301 | 301 | 300 | 300 | 299 | 298 | 297 | 296 | ||||||
| Retained Earnings Accumulated Deficit | -469 | -453 | -283 | -278 | -274 | -269 | -262 | -254 | -247 | -240 | -232 | -224 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 173 | -137 | 19 | 23 | 27 | 32 | 38 | 46 | 52 | 58 | 65 | 71 | ||||||
| Liabilities And Stockholders Equity | 189 | 205 | 23 | 28 | 32 | 38 | 45 | 53 | 60 | 67 | 74 | 82 | ||||||
| Series B Redeemable Convertible Preferred Stock | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 13 | 13 | 13 | 250 | 250 | 13 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 26 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 26 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFaeth Therapeutics, Inc. (FTH) — SEC Financial Statements & Analysis
Faeth Therapeutics, Inc. (FTH) is a pharmaceutical preparations company, incorporated in DE. Faeth Therapeutics, Inc. trades on Nasdaq as: FTH. Faeth Therapeutics, Inc. (FTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Faeth Therapeutics, Inc. carries a market cap of $141.08M, a P/E ratio of -0.72x, a P/B ratio of 0.82x, an enterprise value of $114.18M, and an EV/EBITDA multiple of -0.57x. On profitability, it posts a Return on Equity (ROE) of -195.26%, a Return on Assets (ROA) of -176.88%, and a Return on Invested Capital (ROIC) of -246.74%. Per share, it reports EPS of $-34.65, diluted EPS of $-34.65, free cash flow per share of $-6.00, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 628.96% year-over-year and EPS growth of 62.87% year-over-year. On the balance sheet, it maintains a current ratio of 19.69x, a quick ratio of 19.55x, working capital of $179.08M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.05, an interest coverage ratio of -22091.11x, free cash flow of $-33.86M (TTM), and net debt of $-26.90M. Figures sourced from SEC EDGAR.
- Market Cap
- $141.08M
- P/E TTM
- -0.72x
- EPS TTM
- $-34.65
- P/B TTM
- 0.82x
- ROE TTM
- -195.26%
- ROA TTM
- -176.88%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-33.86M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Faeth Therapeutics, Inc. in?
Faeth Therapeutics, Inc. (FTH) operates in the Pharmaceutical Preparations industry.
What exchange does FTH trade on?
Faeth Therapeutics, Inc. (FTH) trades on the Nasdaq.
Where is Faeth Therapeutics, Inc. incorporated?
Faeth Therapeutics, Inc. is incorporated in DE.
When was Faeth Therapeutics, Inc. (FTH)'s most recent SEC filing?
Faeth Therapeutics, Inc. (FTH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is FTH's market cap?
Faeth Therapeutics, Inc. (FTH) has a market capitalization of $141.08M as of 2026-06-30.
What is FTH's EPS (earnings per share)?
Faeth Therapeutics, Inc. (FTH)'s trailing twelve month EPS is $-34.65 as of 2026-06-30.
What is FTH's ROE (return on equity)?
Faeth Therapeutics, Inc. (FTH)'s trailing twelve month Return on Equity (ROE) is -195.26% as of 2026-06-30.
What is FTH's ROA (return on assets)?
Faeth Therapeutics, Inc. (FTH)'s trailing twelve month Return on Assets (ROA) is -176.88% as of 2026-06-30.
What is FTH's ROIC (return on invested capital)?
Faeth Therapeutics, Inc. (FTH)'s trailing twelve month Return on Invested Capital (ROIC) is -246.74% as of 2026-06-30.
What is FTH's EV/EBITDA?
Faeth Therapeutics, Inc. (FTH)'s trailing twelve month EV/EBITDA is -0.57x as of 2026-06-30.